Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company with deep historical roots, having been founded in 1974 as a plasma-derived therapeutics enterprise. Originally incorporated as PlasmaTech Biopharmaceuticals, Inc., the company underwent a strategic rebranding and corporate transformation in June 2015—adopting the name Abeona Therapeutics Inc. to reflect its pivot toward cutting-edge gene and cell therapy innovation. Headquartered in Cleveland, Ohio, Abeona’s foundational mission centers on developing transformative, one-time curative treatments for ultra-rare, life-threatening monogenic diseases—particularly those with high unmet medical need and limited or no FDA-approved therapies. Guided by scientific rigor and patient-centricity, the company has evolved from a legacy plasma-focused entity into a vertically integrated gene therapy developer with proprietary vector engineering capabilities, clinical-stage assets, and an expanding regulatory footprint across the United States and internationally. Its leadership team comprises seasoned executives with decades of experience in rare disease drug development, regulatory strategy, and commercialization in the biotech sector.
Abeona’s current pipeline is anchored by ZEVASKYN (formerly ABO-202), an autologous, ex vivo lentiviral gene therapy approved by the U.S. Food and Drug Administration in March 2024 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in pediatric and adult patients. This landmark approval marked Abeona’s transition to a commercial-stage company and represents the first-ever gene therapy for RDEB—a devastating, blistering skin disorder caused by mutations in the COL7A1 gene. Beyond ZEVASKYN, Abeona is advancing multiple next-generation adeno-associated virus (AAV)-based ocular gene therapies through its proprietary AIM (Adeno-Associated Virus Integrated Mapping) vector platform: ABO-503 targets X-linked retinoschisis (XLRS), ABO-504 addresses Stargardt disease (ABCA4-related), and ABO-505 is designed for autosomal dominant optic atrophy (ADOA, OPA1-related). The AIM platform enables rational vector design via deep mutational scanning, capsid engineering, and tissue-specific promoter optimization—enhancing transduction efficiency, reducing immunogenicity, and improving biodistribution in retinal and optic nerve tissues. Additionally, Abeona maintains internal cGMP manufacturing capabilities for both lentiviral and AAV vectors, supporting clinical supply and long-term commercial scalability.
Abeona operates primarily in the United States, with its commercial infrastructure focused on specialty pharmacies, academic medical centers, and rare disease treatment hubs. While currently U.S.-centric in revenue generation, the company is actively pursuing regulatory pathways in the European Union (via EMA submission for ZEVASKYN), the United Kingdom (MHRA), and Canada (Health Canada), with plans to expand access through health technology assessment (HTA) engagements and managed access agreements. Its target demographic comprises patients with ultra-orphan genetic disorders—many under age 18—with estimated global prevalence ranging from ~1,000 to ~10,000 individuals per indication. Due to the profound morbidity, early mortality, and lifelong caregiving burden associated with these conditions, Abeona’s therapies serve not only patients but also families, payers, and healthcare systems seeking durable, cost-effective alternatives to chronic supportive care. The company collaborates closely with patient advocacy groups—including DEBRA International, Foundation Fighting Blindness, and the Optic Atrophy Coalition—to co-develop clinical trial protocols, support natural history studies, and ensure real-world evidence generation.
Looking ahead, Abeona’s strategic direction emphasizes three pillars: (1) maximizing ZEVASKYN’s commercial adoption through payer contracting, physician education, and patient support services—including its proprietary ‘Abeona CareConnect’ program; (2) advancing its ocular pipeline toward pivotal Phase 3 trials and potential regulatory submissions between 2025–2027, supported by robust biomarker validation and novel endpoint development (e.g., OCT-based structural metrics, microperimetry, and visual function QoL instruments); and (3) leveraging the AIM platform to expand into additional CNS and neuromuscular indications, including exploratory programs in mitochondrial disorders and lysosomal storage diseases. Capital allocation priorities include disciplined R&D investment, strategic partnerships for non-U.S. commercialization, and selective business development—potentially including platform licensing or co-development arrangements. Abeona also intends to strengthen its translational science capabilities through AI-driven vector design and predictive toxicology modeling, positioning itself as a leader in precision gene therapy for inherited sensory and structural disorders.